An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1279-1288

  Kermer, Vanessa ^a   Baum, Volker ^a   Hornig, Nora ^a   Kontermann, Roland E ^a   Müller, Dafne ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 15 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; SEPRASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; GELATINASES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 84862565032     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0019     Document Type: Article

References (35)

1. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93. (Pubitemid 39576919)
2. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002;13:169-83. (Pubitemid 34229391)
3. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2011;33:35-41
4. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-403. (Pubitemid 24289613)
5. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-8. (Pubitemid 24196167)
6. deJong JL, Farner NL, Javorsky BR, Lindstrom MJ, Hank JA, Sondel PM. Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy. Clin Cancer Res 1998;4:1287-96. (Pubitemid 28213342)
7. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-80.
8. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011;22:99-108.
9. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000;97:11445-50.
10. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480-90.
11. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002;17:537-47. (Pubitemid 35351500)
12. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010;127:85-92.
13. Olsen SK, Ota N, Kishishita S, Kukimoto-Niino M, Murayama K, Uchiyama H, et al. Crystal structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation. J Biol Chem 2007;282:37191-204.
14. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004;173:1681-8. (Pubitemid 38971599)
15. Badoual C, Bouchaud G, Agueznay Nel H, Mortier E, Hans S, Gey A, et al. The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008;68:3907-14.
16. Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, Eisenmann J, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995;165:289-93.
17. Tang F, Zhao LT, Jiang Y, Ba de N, Cui LX, He W. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol 2008;5:189-96.
18. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67:4940-8. (Pubitemid 46910202)
19. Kimura K, Nishimura H, Hirose K, Matsuguchi T, Nimura Y, Yoshikai Y. Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency. Eur J Immunol 1999;29:1532-42. (Pubitemid 29224458)
20. Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, Comes A. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000;87:574-81. (Pubitemid 30639819)
21. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2002;99:573-8. (Pubitemid 34461611)
22. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005;105:721-7. (Pubitemid 40070758)
23. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R {alpha}. Proc Natl Acad Sci U S A 2006;103:9166-71. (Pubitemid 43902550)
24. Stoklasek TA, Schluns KS, Lefrançois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072-80. (Pubitemid 44628822)
25. Dubois S, Patel HJ, Zhang M, Waldmann TA,Müller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008;180:2099-106.
26. Bessard A, Solé V, Bouchaud G, Quém'ener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009;8:2736-45.
27. Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, et al. IL-15 transpresentation promotes both human Tcell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A 2011;108:6217-22.
28. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007;282:12650-60. (Pubitemid 47100581)
29. Stork R, Campigna E, Robert B, Müller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009;284:25612-9.
30. Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, et al. Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med 2001;7:461-9. (Pubitemid 33701967)
31. Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J. The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem 2006;281:6642-7. (Pubitemid 43847599)
32. Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006;281:1612-9.
33. Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, et al. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008;382:1-12.
34. Rowley J, Monie A, Hung CF, Wu TC. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred Tcell function in cis. Eur J Immunol 2009;39:491-506.
35. Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 1996;88:230-5. (Pubitemid 26230691)